161 related articles for article (PubMed ID: 33088516)
1. Oral hyperpigmentation associated with hydroxyurea in a patient with polycythemia vera: A case report.
Alshammasi B; Albasry Z; Meshikhes F
Clin Case Rep; 2020 Oct; 8(10):1904-1909. PubMed ID: 33088516
[TBL] [Abstract][Full Text] [Related]
2. Late-Onset Hydroxyurea-Induced Melanonychia and Tongue Hyperpigmentation in a Patient With Polycythemia Vera: A Case Report.
Letete N; Vaz D
Cureus; 2024 Feb; 16(2):e53642. PubMed ID: 38449930
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea-induced hyperpigmentation with iron deposition.
Lee KP; Vangipuram RK; Klimas NK; Sanyal S; Koshelev MV
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735009
[TBL] [Abstract][Full Text] [Related]
4. Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera.
Gropper CA; Don PC; Sadjadi MM
Int J Dermatol; 1993 Oct; 32(10):731-3. PubMed ID: 8225715
[No Abstract] [Full Text] [Related]
5. [Treatment with hydroxyurea of polycythemia vera in a 11 year-old child].
Vodoff MV; Nelken B; Vic P; Farriaux JP
Arch Pediatr; 1996 Sep; 3(9):870-3. PubMed ID: 8949347
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous effects after prolongaded use of hydroxyurea in Polycythemia Vera.
França ER; Teixeira MA; Matias Kde F; Antunes DE; Braz Rde A; Silva CE
An Bras Dermatol; 2011; 86(4):751-4. PubMed ID: 21987143
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea for Treatment of Nephrotic Syndrome Associated With Polycythemia Vera.
Hundemer GL; Rosales IA; Chen YB; Colvin RB; Tolkoff-Rubin NE
Am J Kidney Dis; 2016 Sep; 68(3):465-8. PubMed ID: 27133437
[TBL] [Abstract][Full Text] [Related]
8. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
[TBL] [Abstract][Full Text] [Related]
9. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
Das S; Karachiwala H; Cherian SV; Garcha AS; Jasti S; Gajra A
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):746-8. PubMed ID: 21885951
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera presenting with pulmonary embolism and splenic infarction: a case report.
Huang P; Li Y
J Int Med Res; 2022 Jan; 50(1):3000605211072801. PubMed ID: 35023386
[TBL] [Abstract][Full Text] [Related]
12. Management of hydroxyurea resistant or intolerant polycythemia vera.
Raman I; Pasricha SR; Prince HM; Yannakou CK
Leuk Lymphoma; 2021 Oct; 62(10):2310-2319. PubMed ID: 33949918
[TBL] [Abstract][Full Text] [Related]
13. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychiatric Derangement by Polycythemia Vera: A Case Report of an Unexpected Disease Presentation and Review of the Literature.
De Lil H; van Beek M; Herbers A; van der Holst E; Keijsers K
Acta Haematol; 2021; 144(6):706-711. PubMed ID: 34247161
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
16. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea induced perimalleolar ulcers.
Saravu K; Velappan P; Lakshmi N; Shastry BA; Thomas J
J Korean Med Sci; 2006 Feb; 21(1):177-9. PubMed ID: 16479088
[TBL] [Abstract][Full Text] [Related]
18. Cerebral Hemorrhage of a 50-Year-Old Female Patient with Polycythemia Vera.
Chen L; Xiao H; Hu Z
J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):e110-e112. PubMed ID: 31126786
[TBL] [Abstract][Full Text] [Related]
19. Leg ulcers associated with long-term hydroxyurea therapy.
Weinlich G; Schuler G; Greil R; Kofler H; Fritsch P
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 2):372-4. PubMed ID: 9703157
[TBL] [Abstract][Full Text] [Related]
20. Squamous Cell Carcinoma as a Complication of Long-Term Hydroxyurea Treatment.
Lewandowski M; Łukowicz P; Jankau J; Romantowski J; Barańska-Rybak W
Case Rep Dermatol; 2021; 13(3):542-546. PubMed ID: 35082616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
